All in on ide-cel, Bristol Myers Squibb writes off $470M as second BCMA CAR-T is ejected from the pipeline
With just a little over a month to go before the FDA is slated to decide on ide-cel, Bristol Myers Squibb is writing off $470 million as it scraps a second BCMA CAR-T, dubbed orva-cel.
While ide-cel was the subject of a Celgene collaboration with bluebird bio, orva-cel was originally developed by Juno Therapeutics, which Celgene snapped up for $9 billion before getting acquired by Bristol Myers Squibb itself.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
